Aisling Capital Management LP Makes New $762,000 Investment in OnKure Therapeutics (NASDAQ:OKUR)

Aisling Capital Management LP purchased a new position in shares of OnKure Therapeutics (NASDAQ:OKUR - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 88,607 shares of the company's stock, valued at approximately $762,000. OnKure Therapeutics makes up approximately 0.3% of Aisling Capital Management LP's portfolio, making the stock its 14th largest position. Aisling Capital Management LP owned approximately 2.65% of OnKure Therapeutics at the end of the most recent reporting period.

Separately, Geode Capital Management LLC purchased a new stake in shares of OnKure Therapeutics during the fourth quarter valued at approximately $659,000. Hedge funds and other institutional investors own 90.98% of the company's stock.

OnKure Therapeutics Stock Down 19.5 %

Shares of OKUR stock traded down $0.76 during mid-day trading on Friday, reaching $3.13. 309,491 shares of the company were exchanged, compared to its average volume of 82,785. The company has a 50 day moving average price of $5.10. The company has a market capitalization of $42.05 million, a P/E ratio of -0.26 and a beta of 0.35. OnKure Therapeutics has a fifty-two week low of $3.05 and a fifty-two week high of $20.00.

OnKure Therapeutics (NASDAQ:OKUR - Get Free Report) last announced its quarterly earnings data on Monday, March 10th. The company reported ($1.37) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.51). As a group, research analysts forecast that OnKure Therapeutics will post -4.05 earnings per share for the current fiscal year.

Remove Ads

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on OKUR. HC Wainwright decreased their target price on shares of OnKure Therapeutics from $40.00 to $34.00 and set a "buy" rating for the company in a research note on Tuesday, March 18th. Oppenheimer decreased their price objective on shares of OnKure Therapeutics from $35.00 to $30.00 and set an "outperform" rating for the company in a research report on Tuesday, March 11th. Three equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $32.33.

OnKure Therapeutics Profile

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.